JIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin

Stock News

13小时前

The company JIANGXI BIO (ASX: 06915) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary tetanus antitoxin product.

The veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It works by neutralizing the tetanus toxin, providing passive immunity to animals at risk of infection.

The board of directors believes that securing this approval further enriches the group's product portfolio. This development lays a foundation for the group's continued expansion in the animal health market and is expected to help enhance the group's overall competitiveness and long-term growth potential.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1131987482"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1131987482\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1131987482?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 06:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131987482","market":"other","top_or_hot":-1,"title":"JIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin","media":"Stock News","content":"<p>The company <b>JIANGXI BIO</b> (<b>ASX: 06915</b>) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary tetanus antitoxin product.<br><br>\nThe veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It works by neutralizing the tetanus toxin, providing passive immunity to animals at risk of infection.<br><br>\nThe board of directors believes that securing this approval further enriches the group's product portfolio. This development lays a foundation for the group's continued expansion in the animal health market and is expected to help enhance the group's overall competitiveness and long-term growth potential.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJIANGXI BIO's Wholly-Owned Subsidiary Secures Regulatory Approval for Veterinary Tetanus Antitoxin\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-03 06:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The company <b>JIANGXI BIO</b> (<b>ASX: 06915</b>) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary tetanus antitoxin product.<br><br>\nThe veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It works by neutralizing the tetanus toxin, providing passive immunity to animals at risk of infection.<br><br>\nThe board of directors believes that securing this approval further enriches the group's product portfolio. This development lays a foundation for the group's continued expansion in the animal health market and is expected to help enhance the group's overall competitiveness and long-term growth potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06915","symbol_name":"江西生物","start_time":0,"source_url":"","article_id":"1131987482","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131987482","pubTimestamp":1783033063,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"The company JIANGXI BIO (ASX: 06915) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06915":"江西生物"},"translate_title":"江西生物全资子公司兽用破伤风抗毒素获监管批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06915":1},"content_text":"The company JIANGXI BIO (ASX: 06915) has announced that its wholly-owned subsidiary, Chifeng Boen Pharmaceutical Co., Ltd., has recently obtained the official approval document for its veterinary tetanus antitoxin product.\nThe veterinary tetanus antitoxin is primarily used for the prevention and treatment of tetanus infections in animals. It works by neutralizing the tetanus toxin, providing passive immunity to animals at risk of infection.\nThe board of directors believes that securing this approval further enriches the group's product portfolio. This development lays a foundation for the group's continued expansion in the animal health market and is expected to help enhance the group's overall competitiveness and long-term growth potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}